Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Parallel-Group Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke

Trial Profile

A Randomised, Double-Blind, Parallel-Group Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Desmoteplase (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms DIAS-4
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 01 Nov 2016 Primary endpoint (Modified Rankin Scale Score (mRS) (Percentage of Participants With mRS Scores 0-2) has not been met, according to results published in the Stroke.
    • 01 Nov 2016 Results of the study including post hoc pooled analysis of the concomitant DIAS-3, DIAS-4, and DIAS-J trials published in the Stroke.
    • 08 Oct 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top